Seelos Therapeutics, Inc. (SEEL) financial statements (2022 and earlier)

Company profile

Business Address 300 PARK AVENUE
NEW YORK, NY 10022
State of Incorp. NV
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments78,73415,66210,2613,5796,3312,0873,887
Cash and cash equivalents78,73415,66210,2613,5796,3312,0873,887
Restricted cash and investments      280
Receivables     530519
Inventory, net of allowances, customer advances and progress billings     764469
Inventory     764469
Prepaid expense246      
Other undisclosed current assets4,4811,8328351062612531,136
Total current assets:83,46117,49411,0963,6856,5923,6346,291
Noncurrent Assets
Operating lease, right-of-use asset39  
Property, plant and equipment   38791,0061,290
Other noncurrent assets   373560274
Total noncurrent assets:39  751141,0661,564
TOTAL ASSETS:83,50017,49411,0963,7606,7064,7007,855
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,4213,8112,7151,1511,5714,6446,146
Accounts payable1,6931,887796235589601,580
Accrued liabilities3,7281,9241,9196446503,0703,343
Employee-related liabilities   2728636141,223
Debt1,0302,431   6,6509,475
Derivative instruments and hedges, liabilities4241,062963    
Disposal group, including discontinued operation   21   
Deferred revenue and credits12 137
Other undisclosed current liabilities1,4121257,100    
Total current liabilities:8,2877,42910,7781,1721,58311,29415,758
Noncurrent Liabilities
Long-term debt and lease obligation17,8907,293     
Long-term debt, excluding current maturities17,8907,293     
Liabilities, other than long-term debt   167529222,041
Other liabilities   165876200
Derivative instruments and hedges, liabilities    6948461,841
Other undisclosed noncurrent liabilities 200325    
Total noncurrent liabilities:17,8907,493325167529222,041
Total liabilities:26,17714,92211,1031,1882,33512,21617,799
Stockholders' equity
Stockholders' equity attributable to parent, including:57,3232,572(7)2,5724,371(7,516)(9,944)
Common stock10554272815850
Additional paid in capital198,42877,68056,027327,773320,343308,784298,881
Retained earnings (accumulated deficit)141,210(75,162)(56,061)(325,229)(315,987)(316,308)(308,875)
Other undisclosed stockholders' equity attributable to parent(282,420)      
Total stockholders' equity:57,3232,572(7)2,5724,371(7,516)(9,944)
TOTAL LIABILITIES AND EQUITY:83,50017,49411,0963,7606,7064,7007,855

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues11345375 5115,7634,839
Revenue, net5115,7634,839
Net investment income11345151    
Cost of revenue
(Cost of Goods and Services Sold)
     (3,891)(922)
Gross profit:11345375 5111,8723,917
Operating expenses(61,669)(18,759)(30,122)(9,148)(10,675)(15,279)(25,267)
Other undisclosed operating loss(113)(45)  (511)  
Operating loss:(61,669)(18,759)(29,747)(9,148)(10,675)(13,407)(21,350)
Nonoperating income (expense)(4,379)(342)(21,508)(70)(1,074)5,9742,327
Interest and debt expense2,387(164)(29) (100)(1,000)(800)
Net loss:(63,661)(19,265)(51,284)(9,218)(11,849)(8,433)(19,823)
Other undisclosed net income (loss) attributable to parent(2,387)16429(24)12,1701,000800
Net income (loss) available to common stockholders, diluted:(66,048)(19,101)(51,255)(9,242)321(7,433)(19,023)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(63,661)(19,265)(51,284)(9,218)(11,849)(8,433)(19,823)
Comprehensive loss, net of tax, attributable to parent:(63,661)(19,265)(51,284)(9,218)(11,849)(8,433)(19,823)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: